Sutro Biopharma Achieves First In Human Milestone In Cytokine Derivatives Collaboration With Merck
Sutro Biopharma, Inc., A Clinical-Stage Oncology Company Pioneering Site-Specific And Novel-Format Antibody Drug Conjugates (Adcs), Today Announced That The First Patient Has Been Dosed In A Phase 1 Study Of An Investigational Candidate Resulting From The Collaboration Between Sutro And Merck, Known As Msd Outside The United States And Canada, For The Development Of A Novel Cytokine Derivative Therapeutic For The Treatment Of Cancer. As A Result Of This Milestone, Sutro Will Receive A $10 Million Payment From Merck.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
